13 Mar 2020 07:00
Spire Healthcare Group plc
Â
("Spire Healthcare", "the Company" or "the Group")
Â
NHS COVID-19 support
Â
13 March 2020
Â
Spire Healthcare (LSE: SPI), a leading UK independent hospital group, today announces that following a meeting with NHS England and representatives from across the private sector to discuss future COVID-19 planning, Spire Healthcare has been asked for, and has offered, its support to the NHS during this challenging time.
Â
The exact nature, extent and the timing of this support is yet to be determined; in the meantime, we continue to offer a full service to our patients. We will update the market when further information is available.
Â
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Â
Â
For further information please contact:
Â
Spire Healthcare Cora McCallum, Head of Investor Relations | Â +44 (0)20 7427 9169 Â |
Instinctif Partners Guy Scarborough Damian Reece | Â +44 (0)7917 178 920 +44 (0)7931 598 593 |
Â
Â
Registered Office and Head Office:
Â
Spire Healthcare Group plc
3 Dorset Rise
London
EC4Y 8EN
Registered number 09084066
Â
Â
About Spire Healthcare
Â
Spire Healthcare is a leading independent hospital group in the United Kingdom, with 39 private hospitals and 8 clinics across England, Wales and Scotland.
Â
Working in partnership with around 7,300 experienced consultants, Spire Healthcare delivered tailored, personalised care to approximately 810,000 in-patients and daycase patients in 2019, and is the leading private provider, by volume, of knee and hip operations in the United Kingdom.
Â
The Group's well located and scalable hospitals have delivered successful and award-winning clinical outcomes, positioning the Group well with patients, consultants, the NHS, GPs and Private Medical Insurance ("PMI") providers. 85% of Spire Healthcare's hospitals are rated Good or Outstanding by the CQC (or the equivalent in Scotland and Wales).
Â
Spire treats patients through a variety of routes including PMI, Self-pay and the NHS, providing the Group with diversified access to the expected growth opportunities in the UK healthcare market, which faces significant supply challenges as a result of NHS budget constraints and increasing demand from a growing population with longer life expectancy.